Skip to content
value.today

DTx Pharma, LLC

🇺🇸 San Diego, California, USAPharmaceuticalsFounded 2017
Total raised
$113 M
3 rounds on record
Latest round
$100 M
Feb 2021
First round on record
Aug 2017
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of DTx Pharma, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$100 MNo. 3$50 to $250 million

DTx Pharma, LLC: Raise no. 3, Feb 2021

Investors in this round

22 investors had bought by the notice of Mar 10, 2021: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur Suckow · Executive Officer, Director
  • Jeffrey Friedman · Executive Officer, Director
  • Niki Upper · Executive Officer
  • Andrew Adams · Director
  • Daniel Becker · Director
  • John Rundy · Director
  • Matthew Hammond · Director
  • Tim Scott · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes $205,523.29 of cancellation of indebtedness and $99,999,985.24 of new cash.”

Signed by Arthur Suckow, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 10, 2021. Read the notice at the SEC.

equitySEC
Apr 2019$12 MNo. 2$10 to $50 million

DTx Pharma, LLC: Raise no. 2, Apr 2019

Investors in this round

60 investors had bought by the notice of Sep 20, 2019: 60 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $13 M offered; $1 M still to sell
Smallest investment taken
$10,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arthur T Suckow · Executive Officer, Director
  • Jeffrey T Friedman · Director
  • John T Grundy · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “No finders or salesman engaged”

Signed by Arthur Suckow, Ceo. Source: SEC Form D and 1 amendment, newest notice filed Sep 20, 2019. Read the notice at the SEC.

equitySEC
Aug 2017$1 MNo. 1Under $2 million

DTx Pharma, LLC: Raise no. 1, Aug 2017

Investors in this round

15 investors had bought by the notice of Jun 15, 2018: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
$1
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • Arthur T Suckow · Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “No finders or salesman engaged”

Signed by Arthur T Suckow, Authorized Person. Source: SEC Form D, newest notice filed Jun 15, 2018. Read the notice at the SEC.

optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • DTx Pharma, LLC chose not to state its revenue in its newest notice of a funding round (Mar 2021).

    SEC Form D · Mar 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2021

That is all the official record says: DTx Pharma, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of DTx Pharma, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 60 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by DTx Pharma, LLC
NameRoleNamed in
Arthur SuckowExecutive officerMar 2021
Jeffrey FriedmanExecutive officerMar 2021
Niki UpperExecutive officerMar 2021
Arthur T SuckowExecutive officerSep 2019
Andrew AdamsDirectorMar 2021
Arthur SuckowDirectorMar 2021
Daniel BeckerDirectorMar 2021
Jeffrey FriedmanDirectorMar 2021
John RundyDirectorMar 2021
Matthew HammondDirectorMar 2021
Tim ScottDirectorMar 2021
Arthur T SuckowDirectorSep 2019
Jeffrey T FriedmanDirectorSep 2019
John T GrundyDirectorSep 2019